Latest Thalidomide Stories
Response Rate Increases to 41% and Median Overall Survival Reported at 25 Months for All Evaluable Patients QUEBEC CITY, Dec. 7 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.
NEW YORK, Dec. 7 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc.
NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc.
NEW ORLEANS, Dec. 7 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from an ongoing Phase 2 study, known as the 004 study, of the company's lead proteasome inhibitor, carfilzomib.
NEW YORK, Dec.
'Renaissance' in use may lead to new treatments for controversial drug.
A British man Sunday said he will protest the government's refusal to compensate victims of the drug Thalidomide, administered to their mothers while pregnant.
NEW YORK, Aug. 25 /PRNewswire/ -- Beth R. Jacobson (formerly Beth R.
The International Myeloma Foundation (IMF)â€”supporting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians
QUEBEC CITY, Aug. 3 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS, TSX: AEZ), ("the Company") a global biopharmaceutical company focused on endocrine therapy and oncology, today announced that Keryx Biopharmaceuticals, Inc.
- The act of sweetening by admixture of some saccharine substance.